FDA approves Merck's Winrevair | Drug Store News drugstorenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from drugstorenews.com Daily Mail and Mail on Sunday newspapers.
Adults with pulmonary arterial hypertension (PAH) have a new treatment available with the FDA approval of sotatercept (Winrevair; Merck), an activin signaling inhibitor biologic.
WINREVAIR on top of background therapy significantly improved exercise capacity and multiple important secondary outcome measures compared to background therapy alone
The FDA approval marks a milestone for Merck, which acquired the pulmonary arterial hypertension treatment in 2021 through its $11.5 billion buyout of Acceleron Pharma.
Pulmonary Arterial Hypertension Patients Receive Lifeline With FDA's Approval of New Drug theepochtimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theepochtimes.com Daily Mail and Mail on Sunday newspapers.